-
In this issue: Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.
-
Forty-one women with symptomatic, histologically proven endometriosis (Stages 1-4) were randomized to receive either a contraceptive implant (Implanon®) or depot medroxyprogesterone acetate (DMPA).
-
-
Strides in lowering teen pregnancy rates have been reversed. The latest report from Centers for Disease Control and Prevention's National Center for Health Statistics shows that the teen birth rate increased in more than half of all 50 states in 2006, reversing a 14-year drop in numbers.
-
Your next patient is a 16-year-old female who says she has a burning sensation when urinating. She has a steady boyfriend, but they have never discussed condom use. What is your next move?
-
Despite the safety and efficacy of the Copper T intrauterine device (ParaGard IUD, Barr Pharmaceuticals; Pomona, NY), the levonorgestrel intrauterine system (Mirena IUS, Bayer HealthCare Pharmaceuticals; Wayne, NJ), and the single-rod contraceptive implant (Implanon, Organon; Roseland, NJ), the most popular methods in the United States are oral contraceptives (OCs) and sterilization.
-
Cervical cancer, once one of the most common cancers affecting U.S. women, now ranks 14th in frequency among American women. Thanks to the introduction of the Papanicolaou (Pap) smear, the incidence of invasive cervical cancer has seen a dramatic drop. Between 1955 and 1992, U.S. cervical cancer incidence declined by 74%.
-
Thinking of new ways to reach out to patients? Planned Parenthood Columbia Willamette (PPCW) in Portland, OR, has linked services to the Internet.
-
When it comes to HIV in the United States, young people are disproportionately at risk: An estimated 50% of new HIV infections occur among those under age 25.
-
Use of the benzodiazepine-like hypnotics (z-hypnotics), zolpidem and zopiclone, is associated with an increased risk of crash, particularly in young people.
